Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data?

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. COMPASS Pathways plc (NASDAQ:CMPS) is one of the best psychedelic stocks on our list.

TheFly reported on July 7 that Oppenheimer reaffirmed its Outperform rating and $20 price target on CMPS shares following new Phase 3 COMP006 26-week results. The firm stated that the data further support the sustained effectiveness of COMP360 in patients with treatment-resistant depression. Oppenheimer believes the latest findings strengthen the company’s regulatory outlook, including a planned NDA submission in the fourth quarter, while reinforcing the potential for the first FDA approval of a classical psychedelic therapy. The firm also views the stock’s commercial opportunity as not fully reflected in its current valuation ahead of a possible first-half 2027 launch.

Is COMPASS Pathways plc (CMPS) Stock a Psychedelic Medicine Opportunity After Positive COMP360 Data?

On the same day, COMPASS Pathways plc (NASDAQ:CMPS) reported 26-week results from Part B of its ongoing Phase 3 COMP006 study evaluating COMP360 for treatment-resistant depression. The findings showed sustained clinical benefits and confirmed the therapy’s rapid onset of action in a population with long-standing, difficult-to-treat depression. The company said 39% of patients receiving the 25 mg dose achieved a clinically meaningful improvement by Week 6, with benefits generally maintained through Week 26. COMP360 also continued to demonstrate a favorable safety profile.

COMPASS Pathways plc (NASDAQ:CMPS) is a UK-based biotechnology company developing psychedelic-based therapies for mental health disorders. Its lead candidate, COMP360, is a synthetic psilocybin treatment combined with psychological support for treatment-resistant depression.

While we acknowledge the risk and potential of CMPS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CMPS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1